Atlas Trials

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Clinical trial NCT03817411 · UNKNOWN

Trial details

NCT number
NCT03817411
Sponsor
Taizhou EOC Pharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2019-01-25
Primary completion
2020-03-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.